Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have been given a consensus recommendation of “Moderate Buy” by the seven research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $10.80.

Several equities research analysts have weighed in on SANA shares. Citizens Jmp raised Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research report on Tuesday, March 18th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Sana Biotechnology in a report on Thursday, April 24th. Finally, Jefferies Financial Group assumed coverage on Sana Biotechnology in a report on Friday, March 14th. They issued a “buy” rating and a $7.00 price target for the company.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Boxer Capital Management LLC acquired a new position in Sana Biotechnology during the fourth quarter worth $2,518,000. Corient Private Wealth LLC raised its position in shares of Sana Biotechnology by 161.7% during the 4th quarter. Corient Private Wealth LLC now owns 1,182,699 shares of the company’s stock worth $1,928,000 after purchasing an additional 730,699 shares during the last quarter. Millennium Management LLC lifted its stake in Sana Biotechnology by 604.8% in the 4th quarter. Millennium Management LLC now owns 728,901 shares of the company’s stock valued at $1,188,000 after buying an additional 625,481 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Sana Biotechnology by 44.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,557,496 shares of the company’s stock worth $2,538,000 after buying an additional 478,596 shares during the last quarter. Finally, Two Sigma Investments LP increased its stake in Sana Biotechnology by 228.4% during the 4th quarter. Two Sigma Investments LP now owns 480,298 shares of the company’s stock worth $783,000 after buying an additional 334,042 shares in the last quarter. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Price Performance

SANA stock opened at $1.81 on Friday. The stock has a market capitalization of $408.11 million, a PE ratio of -1.29 and a beta of 1.75. Sana Biotechnology has a 52 week low of $1.26 and a 52 week high of $9.49. The firm has a 50 day moving average of $1.93 and a 200 day moving average of $2.49.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.02. On average, equities research analysts expect that Sana Biotechnology will post -1.16 earnings per share for the current year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.